Retatrutide specifications and research profile
Specifications summary
| Designation | Single-peptide triple receptor agonist |
|---|---|
| Also known as | LY3437943; Retatrutide |
| Sequence / composition | Engineered peptide agonist of GIPR, GLP-1R and GCGR |
| Strength | 30mg |
| Presentation | Powder vial |
| Purity | 99%+ HPLC |
| Storage | Store refrigerated at 2-8 C, protected from light. |
| COA | View Retatrutide BT Labs COA - 5 June 2026 |
Description and research context
Retatrutide (LY3437943) is an engineered single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. This three-receptor profile makes it a reference compound for multi-agonist receptor pharmacology.
Structural and signalling studies have examined how retatrutide is recognised by GIPR, GLP-1R and GCGR in receptor-Gs complexes. Laboratory applications include receptor binding, cAMP-response and pathway-bias comparisons; results must be interpreted within the tested model.
Applications in research
- Comparative GIPR, GLP-1R and GCGR binding and activation assays
- cAMP and Gs-coupled signalling measurements
- Structural comparison of single-, dual- and triple-agonist peptide designs
Precautions and interpretation
For controlled laboratory research only. Not for human or veterinary use. The cited findings come from specific biochemical, cellular, structural or preclinical models and must not be treated as usage guidance or evidence of a defined outcome outside those models.
Retatrutide research record
Clear product, batch, storage, dispatch and document information for this powder vial.
Research context
A research peptide studied in preclinical models involving GLP-1, GIP, and glucagon receptor signalling pathways.
Product record
The listing identifies the presentation, specification, storage record, dispatch status, and COA availability for the relevant product or batch.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.